Cover My Eyes (Pain and Heaven)

Upneeq® Wins "Best Eye Drop for Drooping Lids" New Beauty In 13th Annual Beauty Awards

Retrieved on: 
Friday, March 31, 2023

BRIDGEWATER, N.J., March 31, 2023 /PRNewswire-PRWeb/ -- RVL Pharmaceuticals announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner in the professional treatment category as "Best Eye Drop for Drooping Lids" in the NewBeauty 13th Annual Beauty Awards. Upneeq is FDA approved for the treatment of acquired blepharoptosis (droopy eyelids) in adults. It is the second consecutive win for the brand. Upneeq® was awarded the "Best Innovation" in 2022 by this definitive authority in beauty. The 13th Annual NewBeauty Awards issue hits newsstands on April 4, 2023.

Key Points: 
  • BRIDGEWATER, N.J., March 31, 2023 /PRNewswire-PRWeb/ -- RVL Pharmaceuticals announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner in the professional treatment category as "Best Eye Drop for Drooping Lids" in the NewBeauty 13th Annual Beauty Awards.
  • The 13th Annual NewBeauty Awards issue hits newsstands on April 4, 2023.
  • The most common adverse reactions with Upneeq (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.
  • The most common adverse reactions with UPNEEQ (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.

Blackview Launches the World's First 99.44% Anti Blue Light Glasses - Say No to Eye Problems

Retrieved on: 
Wednesday, March 1, 2023

Born from a concern for users' eye health, including blue light blocking, UV protection, and anti-glare, Blackview launches new anti blue light glasses BG802 , which are dedicated to providing users with the best anti blue light eye protection and perfect eye comfort.

Key Points: 
  • Born from a concern for users' eye health, including blue light blocking, UV protection, and anti-glare, Blackview launches new anti blue light glasses BG802 , which are dedicated to providing users with the best anti blue light eye protection and perfect eye comfort.
  • In light of the dual effects of blue light, Blackview BG802 uses Segmented Anti Blue Light Lens, which prevents 99.44% of harmful blue light from digital devices like smartphones, laptops, and PCs while retaining beneficial blue light from sunshine.
  • Then, let's look at how to select anti blue light glasses and the differences between the various lenses of anti blue light glasses in the market.
  • Achieving double blue light blocking with OAR Anti-radiation Coating and Optical Absorptive Substrate, Blackview BG802 offers up to 99.44% anti-blue light blocking with TÜV Rheinland low blue light certification, which is approximately three times the blue light blocking compared to the majority of blue light glasses that only block 30–50% blue light.

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)

Retrieved on: 
Wednesday, November 16, 2022

With this trial, we hope to explore the role that TEPEZZA could have for Japanese patients struggling with active Thyroid Eye Disease.

Key Points: 
  • With this trial, we hope to explore the role that TEPEZZA could have for Japanese patients struggling with active Thyroid Eye Disease.
  • The trial methodology is based on the OPTIC Phase 3 trial conducted in the United States and Europe.
  • We are so grateful for the participation and partnership of those living with Thyroid Eye Disease in Japan and our principal investigators, said Elizabeth H.Z.
  • The need for a non-surgical, non-steroidal treatment option for Thyroid Eye Disease in Japan is significant.

Prevent Blindness Declares Third Annual Thyroid Eye Disease (TED) Awareness Week as Nov. 14-20, 2022

Retrieved on: 
Wednesday, November 9, 2022

CHICAGO, Nov. 9, 2022 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health and safety organization, has declared Nov. 14-20, 2022, as its third annual "Thyroid Eye Disease Awareness (TED) Week." TED, sometimes called Graves' ophthalmopathy or Graves' Eye Disease, is an autoimmune disease in which the immune system causes inflammation and swelling and stimulates the production of muscle tissue and fat behind the eye.

Key Points: 
  • Prevent Blindness to provide Thyroid Eye Disease (TED) educational materials, promote awareness, and offer unique Art Therapy program for patients and care partners
    CHICAGO, Nov. 9, 2022 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health and safety organization, has declared Nov. 14-20, 2022, as its third annual "Thyroid Eye Disease Awareness (TED) Week."
  • Also available is the "Thyroid Eye Disease" episode of the Focus on Eye Health Expert Series , featuring Prevent Blindness President and CEO Jeff Todd interviewing Sara Wester, MD, FACS, professor of clinical ophthalmology at Bascom Palmer Eye Institute, and TED patient Stephen Bander.
  • TED Awareness Week is supported by Horizon Therapeutics , a global biotechnology company focused on rare, autoimmune and severe inflammatory diseases.
  • Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight.

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting

Retrieved on: 
Wednesday, September 28, 2022

The AAO Annual Meeting is among the largest gatherings of ophthalmic physicians, medical personnel, and industry executives in the ophthalmic industry.

Key Points: 
  • The AAO Annual Meeting is among the largest gatherings of ophthalmic physicians, medical personnel, and industry executives in the ophthalmic industry.
  • All educational content of the AAO Annual Meeting is planned by its program committee, and AAO does not endorse, promote, approve or recommend the use of any products, devices or services.
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
  • You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof.

Vyluma Completes Last Patient Visit for Primary Analysis of Pivotal Phase III CHAMP Study Evaluating NVK002 for the Treatment of Myopia Progression in Children

Retrieved on: 
Thursday, September 1, 2022

The CHAMP study has been designed, in collaboration with FDA, to evaluate whether NVK002 eye drops are safe and effective as a treatment for the progression of myopia in children.

Key Points: 
  • The CHAMP study has been designed, in collaboration with FDA, to evaluate whether NVK002 eye drops are safe and effective as a treatment for the progression of myopia in children.
  • With this milestone, Vyluma remains on track for primary analysis readout later this year and regulatory submission in 2023.
  • NVK002 is a proprietary, investigational, preservative-free eye drop administered nightly, which, if approved, would be the first-in-class pharmaceutical treatment for myopia progression in children.
  • Vylumas pipeline of therapies is led by NVK002, an investigational, preservative-free, low-dose atropine eye drop to treat the progression of myopia in children.

Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002

Retrieved on: 
Wednesday, August 3, 2022

The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.

Key Points: 
  • The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.
  • These early completions of patient recruitment across both trials, gives the company a strong headstart in moving towards its goal to lead the market in launching a myopia progression treatment drug.
  • Following this, a New Drug Application ("NDA") submission to the US Food and Drug Administration (the "FDA") is expected in 2023.
  • Dr. Li Xiaoyi (Benjamin), Chairman of the Board of Directors, Executive Director and CEO of Zhaoke Ophthalmology, said, "The early completion of the patient recruitment of NVK002's Phase III clinical trials marks another huge and exciting milestone for Zhaoke Ophthalmology.

Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”

Retrieved on: 
Tuesday, July 19, 2022

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today launched its Switch Your Tox and Love Evolus Forever campaign to encourage consumers to switch their toxin to Jeuveau (prabotulinumtoxinA-xvfs), its flagship neurotoxin product.

Key Points: 
  • Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today launched its Switch Your Tox and Love Evolus Forever campaign to encourage consumers to switch their toxin to Jeuveau (prabotulinumtoxinA-xvfs), its flagship neurotoxin product.
  • Our Switch Your Tox and Love Evolus Forever program is designed to expand adoption and increase market share of Jeuveau by providing our customers with the tools and incentives needed to engage new patients.
  • We are confident that after two treatments, consumers will see and feel the benefits of Jeuveau and will make the switch.
  • Starting today, Evolus practices can begin participating in the program through the companys digital app platform, and consumers can enroll beginning September 1 at participating locations.

Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting

Retrieved on: 
Wednesday, July 6, 2022

VAUGHAN, ON, July 6, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that five presentations highlighting data from the XIPERE® (triamcinolone acetonide injectable suspension) pivotal Phase 3 program will be presented at the American Society of Retina Specialists (ASRS) 40th annual scientific meeting, which will take place in New York from July 13-16, 2022. The presentations will include a new post-hoc analysis of the pivotal Phase 3 trial (PEACHTREE) evaluating outcomes following treatment with XIPERE® in patients with macular edema associated with chronic uveitis.

Key Points: 
  • "At this year's ASRS annual meeting, we look forward to sharing these data with retina specialists on XIPERE, which we launched commercially in March," said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb.
  • Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with uveitis: Outcomes by anatomic subtypes in PEACHTREE.
  • Efficacy of suprachoroidal triamcinolone acetonide injectable suspension in the treatment of macular edema in patients with chronic uveitis.
  • XIPERE(triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

Vyluma and Laboratoires Théa Enter into Licensing Agreement for the Registration and Commercialization of NVK002 in Canada, Mexico, and Select South American Countries

Retrieved on: 
Tuesday, June 14, 2022

This agreement represents an expansion of the previously announced exclusive licensing agreement for the commercialization of NVK002 in Europe and other select countries.

Key Points: 
  • This agreement represents an expansion of the previously announced exclusive licensing agreement for the commercialization of NVK002 in Europe and other select countries.
  • NVK002 is a proprietary, investigational, preservative-free eye drop administered nightly and intended for slowing the progression of myopia in children ages three to 17.
  • In addition, Vyluma will be entitled to tiered royalty payments, ranging from the mid to upper teens, on net sales of NVK002 under the expanded agreement.
  • To learn more about Tha, visit https://www.laboratoires-thea.com/en
    Investor Contact for Nevakar and Vyluma: